Intervention
ranibizumab
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 9 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
9 shownInfluence of Diabetes Control on Treatment of Diabetic Macular Edema With RanibizumabNCT02665689 · 2016-01-18
TERMINATEDA Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)NCT02302079 · 2015-01-12
COMPLETEDAn Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.NCT01908816 · 2013-09-26
COMPLETEDIntravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular GlaucomaNCT02647515 · 2013-01-01
COMPLETEDPF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)NCT01445899 · 2012-02-01
COMPLETEDSafety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)NCT01135914 · 2010-07-01
COMPLETEDRanibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 StudyNCT01077401 · 2010-02-01
COMPLETEDTrabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of RanibizumabNCT00892398 · 2009-03-01
COMPLETEDRanibizumab in Combination With Proton Beam Irradiation for Choroidal MelanomaNCT00765921 · 2008-06-01
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED8
TERMINATED1
Phase mix
PHASE23
PHASE32
PHASE42
NA1
PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.